Marginum Ltd, founded in autumn 2020, is developing next-generation technology for the removal of cancerous tumours. The innovation is based on years of scientific research.
The smart tissue monitor developed by the company detects cancer cells by utilising fluorescence.
“The smart tissue monitor is used to improve treatments and reduce reoperations”, says Adjunct Professor and Resident in neurosurgery, Antti-Pekka Elomaa.
“The monitor is attached to the suction tube used by the surgeon to remove cancer cells. Based on intensity of detected fluorescence, the monitor detects cancer cells from surgical waste”, says CEO Samu Lehtonen.
Initially, the monitor is to be used in the surgical treatment of brain cancer. The device improves the surgeon’s performance because cancer cells can be removed more accurately and damage to healthy tissue is avoided. Healthcare costs will decrease due to lesser need for reoperations.
Marginum is set to begin clinical trials with the smart tissue monitor in autumn.
The original full article in Finnish can be read at Business Kuopio.